| 2025 |
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study |
Articolo in rivista |
Go to |
| 2024 |
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study |
Articolo in rivista |
Go to |
| 2024 |
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors |
Review essay (rassegna critica) |
Go to |
| 2024 |
Scientific Communication and oncology – "The bridge between knowledge and patients" |
Review essay (rassegna critica) |
Go to |
| 2024 |
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) |
Articolo in rivista |
Go to |
| 2024 |
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints |
Review essay (rassegna critica) |
Go to |
| 2024 |
BRCA-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants? |
Articolo in rivista |
Go to |
| 2023 |
Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one? |
Articolo in rivista |
Go to |
| 2023 |
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab |
Articolo in rivista |
Go to |
| 2023 |
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? |
Articolo in rivista |
Go to |
| 2023 |
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay |
Articolo in rivista |
Go to |
| 2023 |
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer |
Articolo in rivista |
Go to |
| 2022 |
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer? |
Articolo in rivista |
Go to |
| 2022 |
Liquid biopsy and immunotherapy: is all that glitter gold? |
Capitolo o Saggio |
Go to |
| 2022 |
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors |
Review essay (rassegna critica) |
Go to |
| 2022 |
Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer |
Articolo in rivista |
Go to |
| 2022 |
Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength |
Articolo in rivista |
Go to |
| 2022 |
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning |
Articolo in rivista |
Go to |
| 2022 |
MUTYH-associated tumor syndrome: The other face of MAP |
Articolo in rivista |
Go to |
| 2022 |
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? |
Articolo in rivista |
Go to |
| 2021 |
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) |
Articolo in rivista |
Go to |
| 2021 |
Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival? |
Articolo in rivista |
Go to |
| 2021 |
POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes |
Review essay (rassegna critica) |
Go to |
| 2021 |
Role of the HIPPO pathway as potential key player in the cross talk between oncology and cardiology |
Articolo in rivista |
Go to |
| 2021 |
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors |
Review essay (rassegna critica) |
Go to |
| 2021 |
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge |
Articolo in rivista |
Go to |
| 2021 |
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome |
Articolo in rivista |
Go to |
| 2020 |
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming |
Articolo in rivista |
Go to |
| 2020 |
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients |
Articolo in rivista |
Go to |
| 2020 |
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions |
Articolo in rivista |
Go to |
| 2020 |
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 |
Articolo in rivista |
Go to |
